Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
The developer of eye drugs has yet to launch a product on the market and could face financial pressure if its latest listing attempt falters Key Takeaways: Cloudbreak has sold…
RELATED ARTICLES
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Xiaocaiyuan sets the table for Hong Kong IPO. But is the timing right?
0999.HK
